Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab dose comparison with PPV in proliferative diabetic retinopathy
ChiCTR2000035032Phase 4Recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Aug 2020
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of ranibizumab in proliferative diabetic retinopathy (PDR) (2 arms), sponsored by Shanghai General Hospital. Primary endpoint: Best corrected visual acuity (BCVA). Started Aug 2020; status: recruiting.
02
Drugs
ranibizumab
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on ChiCTR2000035032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035032.